Citation: A. Blumenthal, and L. Morgentaler, Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation, ResearchGate (not peer-reviewed), 2022/09/15, 10.13140/RG.2.2.12326.19525
Key Tollovid Data: In the following case study, we document a Long COVID patient in whom microclots and hyperactivated platelets are observed. Following standard anti-coagulation therapy, supplementation with Tollovid, a botanical 3CL protease inhibitor, is initiated, which helps improve the patient’s overall trajectory of recovery.